Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Rethinking osteoporosis drugs : can we simultaneously address sarcopenia?
Avtorji:ID Gavrilov, Zoran (Avtor)
ID Lojk, Jasna (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (1,50 MB)
MD5: 73DA1C50B77146960122FC60B4CBEE2A
 
URL URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/1422-0067/26/14/6924
 
Jezik:Angleški jezik
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:Osteoporosis and sarcopenia are two aspects of the geriatric syndrome that frequently occur together and affect one another in a condition referred to as osteosarcopenia. Preventive and treatment options for osteosarcopenia exist but are mainly focused on the treatment of osteoporosis, as there is still no FDA-approved treatment for sarcopenia. Drugs for osteoporosis include antiresorptive and anabolic drugs and hormonal replacement therapies and are prescribed based on age, BMD and other patient characteristics, which, however, do not include the possible co-existence of sarcopenia. As several studies and clinical trials have shown that the pharmacological treatment of osteoporosis can also affect muscle tissue, in either a positive or negative manner, sarcopenia should be another factor affecting the choice of treatment, especially when facing equal treatment options for osteoporosis. The aim of this review was to summarize our current knowledge on the effects of FDA-approved drugs for the treatment of osteoporosis on muscle quality, mass and function. A better understanding of the effects that certain drugs have on muscle tissue might in the future help us to simultaneously at least partially also address the wasting of muscle tissue and avoid further pharmacologically induced decline.
Ključne besede:osteoporosis, sarcopenia, osteosarcopenia, pharmacological treatment
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2025
Št. strani:str. 1-38
Številčenje:Vol. 26, iss. 14
PID:20.500.12556/DiRROS-24639 Novo okno
UDK:61
ISSN pri članku:1422-0067
DOI:10.3390/ijms26146924 Novo okno
COBISS.SI-ID:254168579 Novo okno
Opomba:Nasl. z nasl. zaslona; Opis vira 21. 6. 2021;
Datum objave v DiRROS:09.12.2025
Število ogledov:98
Število prenosov:40
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:International journal of molecular sciences
Skrajšan naslov:Int. j. mol. sci.
Založnik:MDPI
ISSN:1422-0067
COBISS.SI-ID:2779162 Novo okno

Gradivo je financirano iz projekta

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P3-0298-2019
Naslov:Geni, hormonske in osebnostne spremembe pri metabolnih motnjah

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:J3-4527-2022
Naslov:Mišični sekretom in kostne celice - sodelovanje pri osteosarkopeniji (MiKOSA)

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Univerzitetni klinični center Ljubljana
Številka projekta:20230079
Naslov:Uvedba tehnologij LC-MS za podporo personalizirani terapiji (PerTeri-MS)

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Univerzitetni klinični center Ljubljana
Številka projekta:20250236
Naslov:Vpeljava in validacija metode za določanje antibiotikov na tehnologiji LC-MS/MS

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Nazaj